FGFR1 expression defines clinically distinct subtypes in pancreatic cancer

摘要: The clinical significance of fibroblast growth factor receptor 1 (FGFR1) protein expression in pancreatic cancer is largely unknown. In this study, we aimed investigate the FGFR1 cancer. First, investigated relationship between FGFR pathway gene and clinicopathological data three cohorts containing 313 cases. Subsequently, to confirm findings from discovery cohorts, performed immunohistochemistry (IHC) a validation cohort 205 1, Klotho beta (KLB) overexpression was associated with low tumor stage (P < 0.05), grade better overall survival. Multivariate analysis predicted (P < 0.05) as prognostic for 2 3, only survival (P < 0.05). cohort, there were 15.7% 61% strong weak/moderate FGFR1-positive cases, respectively. cases showed than FGFR1-negative Furthermore, multivariate revealed positivity an independent patients (hazard ratio 0.677, 95% confidence interval 0.471–0.972, P = 0.035). expression, estimated by IHC, may be used define clinically distinct subtypes Moreover, FGFR1-based subclassification lead new therapeutic approaches subtype.